Главная › Немелкоклеточный рак легкого › Теннесси

Клинические исследования Немелкоклеточный рак легкого в штате Теннесси

118 исследований по теме Немелкоклеточный рак легкого ищут участников в центрах в штате Теннесси.

Города в штате Теннесси

Официальный текст исследования (на английском)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
Regional Cancer Center at Johnson City Medical Center, Johnson City
Ballad Health Cancer Care - Kingsport, Kingsport
и еще 1

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Tennessee Oncology, PLLC - Chattanooga Downtown ( Site 0315), Chattanooga
Thompson Cancer Survival Center ( Site 0168), Knoxville
Elliston Place Medical Oncology & Hematology ( Site 0215), Nashville

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT06623422

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Tennessee Oncology - Chattanooga - Downtown, Chattanooga
Tennessee Oncology - Chattanooga - GHCR Site I, Chattanooga
Tennessee Oncology - Chattanooga - Memorial Plaza, Chattanooga
и еще 6

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT06472245

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
Baptist Memorial Hospital and Cancer Center-Memphis, Memphis

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Sarah Cannon Research Institute, Nashville

Набор участниковФаза 1/2

Возраст от 12 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT04585750

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Sarah Cannon Research Institute, Nashville
Tennessee Oncology PLLC, Nashville

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT06465069

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Sarah Cannon Research Institute, Nashville

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT07751042

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Tennessee Oncology, Nashville

Набор участниковФаза 2/3

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT07365319

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Tennessee Oncology, Nashville

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #3, Nashville

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

The University of Tennessee Medical Center ( Site 3223), Knoxville

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT07513376

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

SCRI Oncology Partners, Nashville

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT06172478

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Sarah Cannon Research Institute - Pharmacy, Nashville
SCRI Oncology Partners, Nashville

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT07090499

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 277891, Knoxville
SCRI Oncology Partners /ID# 276959, Nashville

Набор участниковФаза 2/3

Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT07155187

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

SCRI Oncology Partners, Nashville

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT06625775

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
Baptist Memorial Hospital and Cancer Center-Memphis, Memphis

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

SCRI Oncology Partners, Nashville
Tennessee Oncology, Nashville

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 30 сент. 2026 г. · NCT07361497

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

SCRI Oncology Partners, Nashville

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 30 сент. 2026 г. · NCT06765109

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Nashville

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 29 сент. 2026 г. · NCT05877599

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

SCRI Oncology Partners - Tennessee, Nashville

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 29 сент. 2026 г. · NCT06881784

A Study of PHN-012 in Patients With Advanced Solid Tumors

PHN-012-001 Site, Nashville

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 29 сент. 2026 г. · NCT07127874

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Baptist Cancer Center, Bartlett
Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
и еще 18

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 28 сент. 2026 г. · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

University of Tennessee Medical Center Knoxville ( Site 0082), Knoxville

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
Tennessee Oncology, PLLC - Chattanooga - Medical Park II, Chattanooga
Tennessee Oncology, PLLC - Franklin, Franklin
и еще 11

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT07222566

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Regional One Health, Memphis
Sarah Cannon Research Institute, Nashville
United States Oncology Regulatory Affairs Corporate Office, Nashville

Набор участниковФаза 3

Возраст от 18 до 100 · Любой пол · Обновлено 25 сент. 2026 г. · NCT05920356

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Nashville

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT06218914

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

University of Tennessee Medical Center, Knoxville

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT07489066

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Vanderbilt University Medical Center, Nashville

Набор участниковНаблюдательное исследование

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT04981119

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Tennessee Oncology - Chattanooga, Chattanooga
Tennessee Cancer Specialists, Knoxville
University of Tennessee, Knoxville
и еще 2

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

University of Tennessee Medical Center, Knoxville
Sarah Cannon Research Institute, Nashville

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT07154290

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Tennessee Oncology Chattanooga, Chattanooga
University of Tennessee Medical Center, Knoxville
Sarah Cannon Research Institute, Nashville
и еще 2

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 24 сент. 2026 г. · NCT06890598

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Vanderbilt University Medical Center, Nashville

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 24 сент. 2026 г. · NCT06047379

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

University of Tennessee Medical Center, Knoxville

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 23 сент. 2026 г. · NCT06618287

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Chattanooga
Research Site, Memphis
Research Site, Nashville
и еще 1

Набор участниковФаза 2

Возраст от 18 до 95 · Любой пол · Обновлено 23 сент. 2026 г. · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

University of Tennessee Medical Center, Knoxville
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville

Набор участниковФаза 2/3

Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT06712316

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Sarah Cannon Research Institue, Nashville

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT06128551

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

SCRI Oncology Partners /ID# 270162, Nashville

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT06568939

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Tennessee Oncology, Nashville

Набор участниковФаза 2/3

Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT07100080

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

SCRI Oncology Partners, Nashville
Local Institution - 0697, Nashville

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT06875310

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sarah Cannon - Tennessee Oncology, Nashville

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 21 сент. 2026 г. · NCT05983432

Источник: ClinicalTrials.gov, данные получены 5 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.